Skip to search formSkip to main contentSkip to account menu

PF-04937319

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Efficacy and safety of glucokinase activators for type 2 diabetes mellitus: A systematic review
Glucokinase activators (GKAs) are newly drug class proposed for diabetes treatment. This systematic review aimed to assess the… 
2019
2019
A novel Css-MRTpo approach to simulate oral plasma concentration–time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite in humans using…
Abstract A Css-MRTpo superposition method was devised to predict (retrospectively) oral plasma concentration–time profiles of PF… 
2017
2017
Pyridoxine dipharmacophore derivatives as potent glucokinase activators for the treatment of type 2 diabetes mellitus
Glucokinase is one of the promising targets for glucose-lowering agents, and the development of GK activators are now considered… 
2014
2014
The Relationship of Glucokinase Activator–induced Hypoglycemia with Arteriopathy, Neuronal Necrosis, and Peripheral Neuropathy in Nonclinical Studies
Glucokinase activators (GKAs) are being developed for the treatment of type 2 diabetes. The toxicity of 4 GKAs (PF-04279405, PF… 
2014
2014
Metabolites in Safety Testing Assessment in Early Clinical Development: A Case Study with a Glucokinase Activator
The present article summarizes Metabolites in Safety Testing (MIST) studies on a glucokinase activator, N,N-dimethyl-5-((2-methyl… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)